Skip to content

Paraspinal Block in Nonspecific Low Back Pain

Study on the Effects of Paraspinal Lidocaine Injection on Nonspecific Low Back Pain

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02387567
Enrollment
378
Registered
2015-03-13
Start date
2007-01-31
Completion date
2013-01-31
Last updated
2015-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Low Back Pain

Brief summary

The purpose of this study is to investigate the effects of a treatment involving the application of lidocaine injected on the low back area for pain control. The study will compare this form of treatment with other options such as physical exercises or pain killer medication, different measurements are going to be used to quantify the response to each of these treatments.

Detailed description

This trial was conducted in the Department of Rehabilitation, Hospital das Clinicas, University, of Sao Paulo Medical School, one of the largest rehabilitation centers in Brazil. The trial was initiated in January of 2007 and close to enrollment in January of 2013. Investigators included patients with a diagnosis of chronic nonspecific low back pain who were referred from various clinics in São Paulo that were linked to this rehabilitation center. Thus, patients were referred primarily by physiatrists, general practitioners, neurologists, orthopedic surgeons, and physiotherapists. Participants were randomized to receive: (i) paraspinal lidocaine injection (LID-INJ) and standard treatment, (ii) sham lidocaine injection (SH-INJ) and standard treatment, or (iii) standard treatment only (STD-TTR). Randomization was performed using a computerized random number generator. Assessments The evaluations were performed by an independent and blinded appraiser before treatment, after 1 week, and 3 months after the end of the applications. Baseline assessments consisted of a demographic and baseline clinical assessment \[gender, age, occupation, duration of pain (months), pain intensity, associated diseases, and usual occupation\] and a physical examination \[measurements of weight and height to calculate body mass index (BMI)\]. Primary Outcome Measure The primary outcome measure was the visual analog scale (VAS) score for pain. The VAS comprised a 10-cm ruler from 0 to 10, with 0 corresponding to no pain and 10 corresponding to maximum pain. Patients were asked to rate their average pain in the preceding 24 hs. Secondary Outcome Measures Investigators also measured low back pain using the Brazilian Roland-Morris tool, which consisted of a specific questionnaire to assess function in patients with low back pain and has been validated in Brazil. Scores range from 0 to 24, wherein higher scores reflect greater disability due to low back pain.

Interventions

DRUGLidocaine

Paraspinal block with 3ml lidocaine injection at 1%.

DRUGSham Lidocaine

Sham injection, without lidocaine.

OTHERStandard treatment

Standard treatment only, without lidocaine or sham injection.

Sponsors

Spaulding Rehabilitation Hospital
CollaboratorOTHER
Marta Imamura
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Age between 20 to 60 years; * Clinical symptoms of vertebral pain that is unresponsive to symptomatic treatment with anti-inflammatory drugs for 3 months; * Moderate to severe pain: visual analog scale (VAS) \> 4; * Diagnosis of chronic nonspecific low back pain; * MiniMental test (MEEM) between 24 and 30; * Availability to comply with the visits; * Agree with signing the Informed Consent Form

Exclusion criteria

* Severe psychiatric disease that requires psychiatric care; * Neurological disorders (lumbosciatic pain); * Concurrent fibromyalgia, per the 1990 diagnostic criteria of the American Academy of Rheumatology * Concurrent rheumatic disease * History of allergy to lidocaine (used for paraspinal blocks) * Labor problems * History of surgery on the lumbar spine * No availability to visit the clinic for treatment and evaluations.

Design outcomes

Primary

MeasureTime frame
Change from baseline in pain on the visual analog scale (VAS) score for pain at week 1Baseline, week 1

Secondary

MeasureTime frame
Change from baseline in pain on the Brazilian Roland-Morris tool at week 1Baseline, week 1
Change from baseline in pain on the Brazilian Roland-Morris tool at week 12baseline, week 12
Change from baseline in pain on the visual analog scale (VAS) score for painBaseline, week 12

Other

MeasureTime frame
Adverse effects questionnaireImmediately after intervention and 3 months post application

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026